CAR-T extends EFS as second-line therapy for advanced B-cell lymphoma, topline data show

375547

Sumary of CAR-T extends EFS as second-line therapy for advanced B-cell lymphoma, topline data show:

  • Lisocabtagene maraleucel extended EFS and PFS compared with high-dose chemotherapy and hematopoietic stem cell transplant for relapsed or refractory large B-cell lymphoma, according to topline data released by the agent manufacturer..
  • Lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) — also known as liso-cel — is a gene edited, autologous CAR T-cell therapy that targets the CD19 antigen expressed on the surface of cancer cells..
  • The FDA approved the treatment earlier this year for adults with relapsed or refractory large B-cell lymphoma who received at least two prior therapies and did not have central nervous system disease..
  • Safety results appeared consistent with previous studies of liso-cel as third-line therapy and no new safety issues have emerged during the TRANSFORM study, according to the press release..
  • “We ambitiously designed the TRANSFORM trial to evaluate Breyanzi potential in the second-line setting for patients with relapsed or refractory large B-cell lymphoma against the standard-of-care regimen of high-dose chemotherapy and autologous stem cell transplant,”.
  • Bristol Myers Squibb plans to conduct a complete analysis of the TRANSFORM trial data and present the results at an upcoming medical conference, according to the press release…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close